CAMP4 Therapeutics Corporation (CAMP) Operating Margin
- Operating margin · 12 months: Value -1254.22%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1254.22% | Operating income / revenue. Period ending 2026-06-30. $-52.88M ÷ $4.22M × 100 ≈ -1254.22% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -52.88M USD | Operating Income (Loss) |
| Revenue | 4.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 38.69M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-52.88M | $4.22M | (m) | $38.69M | (m) | -1254.22% |
| 2026-03-31 | $-52.53M | $3.93M | (m) | $38.22M | (m) | -1335.18% |
| 2025-12-31 | $-52.55M | $3.50M | (m) | $38.20M | (m) | -1502.43% |
| 2025-09-30 | $-53.81M | $3.80M | (m) | $39.84M | (m) | -1415.39% |
| 2025-06-30 | $-53.68M | $3.01M | (m) | $40.18M | (m) | -1785.13% |
| 2025-03-31 | $-53.31M | $1.51M | (m) | $39.22M | (m) | -3530.66% |
| 2024-12-31 | $-53.09M | $652.00K | (m) | $38.82M | (m) | -8142.33% |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-51.88M | $350.00K | (m) | $40.62M | (m) | -14822.57% |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |